NCT03356054View on ClinicalTrials.gov

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

February 28, 2027

Conditions
DLBCL
Interventions
COMBINATION_PRODUCT

R-DHAP

3 cycles q 3 weeks

DRUG

Brentuximab Vedotin

3 cycles q 3 weeks added to R-DHAP

Trial Locations (1)

Unknown

RECRUITING

NL-Rotterdam-ERASMUSMC, Rotterdam

All Listed Sponsors
lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER